Ikarian Capital’s Soleno Therapeutics SLNO Stock Holding History

Ikarian Capital’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-50,000	Closed	-$3.38M	–	215
2025 Q3	$3.38M	Sell	50,000 -150,000	-75%	-$11.1M	0.34%	78
2025 Q2	$16.8M	Buy	200,000 +100,000	+100%	+$7.48M	3.22%	6
2025 Q1	$7.14M	Buy	100,000 +25,000	+33%	+$1.22M	0.88%	23
2024 Q4	$3.37M	Buy	+75,000	New	+$3.89M	0.46%	60
2020 Q3	–	Sell	-78,587	Closed	-$2.62M	–	208
2020 Q2	$2.62M	Buy	+78,587	New	+$3.41M	0.21%	95

Other funds holding SLNO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

KCM

Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Ikarian Capital's SLNO Position: Q1 2026 in Review

Ikarian Capital increased its Soleno Therapeutics (SLNO) stake by 400% in Q1 2026, buying an estimated $10.8M and bringing the position to 344,123 shares worth $11.5M. The position accounts for 0.94% of the portfolio, ranked #29.

Ikarian Capital first reported a position in SLNO in Q2 2020 and has held it in 15 quarters since. The position peaked at $24.2M in Q1 2024. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

Ikarian Capital held 344,123 shares of Soleno Therapeutics worth $11.5M as of Q1 2026.
Ikarian Capital bought 275,300 Soleno Therapeutics shares in Q1 2026, an estimated $10.8M.
Soleno Therapeutics made up 0.94% of Ikarian Capital's portfolio in Q1 2026, its #29 holding.
Ikarian Capital first reported a position in Soleno Therapeutics in Q2 2020 and has held it in 15 quarters since.
Ikarian Capital's Soleno Therapeutics position peaked at $24.2M in Q1 2024.
225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.